Merck
  • Home
  • Search Results
  • A Novel Ruthenium Based Coordination Compound Against Pathogenic Bacteria.

A Novel Ruthenium Based Coordination Compound Against Pathogenic Bacteria.

International journal of molecular sciences (2020-04-16)
Vishma Pratap Sur, Aninda Mazumdar, Pavel Kopel, Soumajit Mukherjee, Petr Vítek, Hana Michalkova, Markéta Vaculovičová, Amitava Moulick
ABSTRACT

The current epidemic of antibiotic-resistant infections urges to develop alternatives to less-effective antibiotics. To assess anti-bacterial potential, a novel coordinate compound (RU-S4) was synthesized using ruthenium-Schiff base-benzimidazole ligand, where ruthenium chloride was used as the central atom. RU-S4 was characterized by scanning electron microscope (SEM), energy-dispersive X-ray spectroscopy (EDS), and Raman spectroscopy. Antibacterial effect of RU-S4 was studied against Staphylococcus aureus (NCTC 8511), vancomycin-resistant Staphylococcus aureus (VRSA) (CCM 1767), methicillin-resistant Staphylococcus aureus (MRSA) (ST239: SCCmecIIIA), and hospital isolate Staphylococcus epidermidis. The antibacterial activity of RU-S4 was checked by growth curve analysis and the outcome was supported by optical microscopy imaging and fluorescence LIVE/DEAD cell imaging. In vivo (balb/c mice) infection model prepared with VRSA (CCM 1767) and treated with RU-S4. In our experimental conditions, all infected mice were cured. The interaction of coordination compound with bacterial cells were further confirmed by cryo-scanning electron microscope (Cryo-SEM). RU-S4 was completely non-toxic against mammalian cells and in mice and subsequently treated with synthesized RU-S4.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Benzimidazole, 98%